212 related articles for article (PubMed ID: 21232002)
1. Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients.
Laporte S; Liotier J; Bertoletti L; Kleber FX; Pineo GF; Chapelle C; Moulin N; Mismetti P
J Thromb Haemost; 2011 Mar; 9(3):464-72. PubMed ID: 21232002
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
3. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Amin AN; Lin J; Lenhart G; Schulman KL
Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
[TBL] [Abstract][Full Text] [Related]
4. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial.
Pineo G; Lin J; Stern L; Subrahmanian T; Annemans L
J Hosp Med; 2012 Mar; 7(3):176-82. PubMed ID: 22058011
[TBL] [Abstract][Full Text] [Related]
5. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
Veeranki SP; Xiao Z; Levorsen A; Sinha M; Shah BR
Am J Cardiovasc Drugs; 2021 Jul; 21(4):443-452. PubMed ID: 33313988
[TBL] [Abstract][Full Text] [Related]
6. Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients.
Samuel S; To C; Ling Y; Zhang K; Jiang X; Bernstam EV
J Thromb Thrombolysis; 2023 Apr; 55(3):439-448. PubMed ID: 36624202
[TBL] [Abstract][Full Text] [Related]
7. Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
Elsaid KA; Collins CM
Am J Health Syst Pharm; 2012 Mar; 69(5):390-6. PubMed ID: 22345418
[TBL] [Abstract][Full Text] [Related]
8. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Mismetti P; Quenet S; Levine M; Merli G; Decousus H; Derobert E; Laporte S
Chest; 2005 Oct; 128(4):2203-10. PubMed ID: 16236875
[TBL] [Abstract][Full Text] [Related]
9. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Jones LE
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD001100. PubMed ID: 28182249
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.
Kahale LA; Matar CF; Hakoum MB; Tsolakian IG; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD006649. PubMed ID: 34878173
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.
Middleton P; Shepherd E; Gomersall JC
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD001689. PubMed ID: 33779986
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
Cochrane Database Syst Rev; 2011 Apr; (4):CD006649. PubMed ID: 21491395
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Deitelzweig SB; Becker R; Lin J; Benner J
Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
[TBL] [Abstract][Full Text] [Related]
19. Short-term therapy with enoxaparin or unfractionated heparin for venous thromboembolism in hospitalized patients: utilization study and cost-minimization analysis.
Argenta C; Ferreira MA; Sander GB; Moreira LB
Value Health; 2011; 14(5 Suppl 1):S89-92. PubMed ID: 21839908
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.
Bain E; Wilson A; Tooher R; Gates S; Davis LJ; Middleton P
Cochrane Database Syst Rev; 2014 Feb; (2):CD001689. PubMed ID: 24519568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
